Optimizing extended-release carbidopa/levodopa in Parkinson disease

Alberto J. Espay, Fernando L. Pagan, Benjamin L. Walter, John Christopher Morgan, Lawrence W. Elmer, Cheryl H. Waters, Pinky Agarwal, Rohit Dhall, William G. Ondo, Kevin J. Klos, Dee E. Silver

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of review: To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD). Recent findings: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice. Summary: Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected. Initial regimens may be based on doubling the patient's preconversion levodopa daily dosage and choosing a division of doses to address the patient's motor complications, e.g., wearing-off (warranting a relatively high ER CD/LD dose, possibly at a lower frequency than for IR CD/LD) or dyskinesia (warranting a relatively low dose, perhaps at an unchanged frequency). Patients should know that the main goal of conversion is a steadier levodopa clinical response, even if dosing frequency is unchanged.

Original languageEnglish (US)
Pages (from-to)86-93
Number of pages8
JournalNeurology: Clinical Practice
Volume7
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

Parkinson Disease
Levodopa
Dyskinesias
Movement Disorders
Pharmacokinetics
levodopa drug combination carbidopa
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Espay, A. J., Pagan, F. L., Walter, B. L., Morgan, J. C., Elmer, L. W., Waters, C. H., ... Silver, D. E. (2017). Optimizing extended-release carbidopa/levodopa in Parkinson disease. Neurology: Clinical Practice, 7(1), 86-93. https://doi.org/10.1212/CPJ.0000000000000316

Optimizing extended-release carbidopa/levodopa in Parkinson disease. / Espay, Alberto J.; Pagan, Fernando L.; Walter, Benjamin L.; Morgan, John Christopher; Elmer, Lawrence W.; Waters, Cheryl H.; Agarwal, Pinky; Dhall, Rohit; Ondo, William G.; Klos, Kevin J.; Silver, Dee E.

In: Neurology: Clinical Practice, Vol. 7, No. 1, 01.02.2017, p. 86-93.

Research output: Contribution to journalReview article

Espay, AJ, Pagan, FL, Walter, BL, Morgan, JC, Elmer, LW, Waters, CH, Agarwal, P, Dhall, R, Ondo, WG, Klos, KJ & Silver, DE 2017, 'Optimizing extended-release carbidopa/levodopa in Parkinson disease', Neurology: Clinical Practice, vol. 7, no. 1, pp. 86-93. https://doi.org/10.1212/CPJ.0000000000000316
Espay, Alberto J. ; Pagan, Fernando L. ; Walter, Benjamin L. ; Morgan, John Christopher ; Elmer, Lawrence W. ; Waters, Cheryl H. ; Agarwal, Pinky ; Dhall, Rohit ; Ondo, William G. ; Klos, Kevin J. ; Silver, Dee E. / Optimizing extended-release carbidopa/levodopa in Parkinson disease. In: Neurology: Clinical Practice. 2017 ; Vol. 7, No. 1. pp. 86-93.
@article{35a9e26ac43e47409b4bbcd358654c44,
title = "Optimizing extended-release carbidopa/levodopa in Parkinson disease",
abstract = "Purpose of review: To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD). Recent findings: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice. Summary: Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected. Initial regimens may be based on doubling the patient's preconversion levodopa daily dosage and choosing a division of doses to address the patient's motor complications, e.g., wearing-off (warranting a relatively high ER CD/LD dose, possibly at a lower frequency than for IR CD/LD) or dyskinesia (warranting a relatively low dose, perhaps at an unchanged frequency). Patients should know that the main goal of conversion is a steadier levodopa clinical response, even if dosing frequency is unchanged.",
author = "Espay, {Alberto J.} and Pagan, {Fernando L.} and Walter, {Benjamin L.} and Morgan, {John Christopher} and Elmer, {Lawrence W.} and Waters, {Cheryl H.} and Pinky Agarwal and Rohit Dhall and Ondo, {William G.} and Klos, {Kevin J.} and Silver, {Dee E.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1212/CPJ.0000000000000316",
language = "English (US)",
volume = "7",
pages = "86--93",
journal = "Neurology: Clinical Practice",
issn = "2163-0402",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Optimizing extended-release carbidopa/levodopa in Parkinson disease

AU - Espay, Alberto J.

AU - Pagan, Fernando L.

AU - Walter, Benjamin L.

AU - Morgan, John Christopher

AU - Elmer, Lawrence W.

AU - Waters, Cheryl H.

AU - Agarwal, Pinky

AU - Dhall, Rohit

AU - Ondo, William G.

AU - Klos, Kevin J.

AU - Silver, Dee E.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose of review: To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD). Recent findings: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice. Summary: Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected. Initial regimens may be based on doubling the patient's preconversion levodopa daily dosage and choosing a division of doses to address the patient's motor complications, e.g., wearing-off (warranting a relatively high ER CD/LD dose, possibly at a lower frequency than for IR CD/LD) or dyskinesia (warranting a relatively low dose, perhaps at an unchanged frequency). Patients should know that the main goal of conversion is a steadier levodopa clinical response, even if dosing frequency is unchanged.

AB - Purpose of review: To help clinicians optimize the conversion of a patient's Parkinson disease pharmacotherapy from immediate-release carbidopa/levodopa (IR CD/LD) to an extended-release formulation (ER CD/LD). Recent findings: Eleven movement disorders specialists achieved consensus positions on the modification of trial-based conversion guidelines to suit individual patients in clinical practice. Summary: Because the pharmacokinetics of ER CD/LD differ from those of IR CD/LD, modification of dosage and dosing frequency are to be expected. Initial regimens may be based on doubling the patient's preconversion levodopa daily dosage and choosing a division of doses to address the patient's motor complications, e.g., wearing-off (warranting a relatively high ER CD/LD dose, possibly at a lower frequency than for IR CD/LD) or dyskinesia (warranting a relatively low dose, perhaps at an unchanged frequency). Patients should know that the main goal of conversion is a steadier levodopa clinical response, even if dosing frequency is unchanged.

UR - http://www.scopus.com/inward/record.url?scp=85012938795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012938795&partnerID=8YFLogxK

U2 - 10.1212/CPJ.0000000000000316

DO - 10.1212/CPJ.0000000000000316

M3 - Review article

AN - SCOPUS:85012938795

VL - 7

SP - 86

EP - 93

JO - Neurology: Clinical Practice

JF - Neurology: Clinical Practice

SN - 2163-0402

IS - 1

ER -